Personalized therapeutic strategies that incorporate ApoB levels, metabolic phenotypes, and advanced lipoprotein profiling offer significant potential to optimize treatment, particularly in complex populations such as individuals with type 2 diabetes mellitus. This evidence concerns the gene APOB and type 2 diabetes mellitus.